Interview with Dr. Paridaens from Hôpital de la Citadelle in Liège: The importance of a fast turnaround time for molecular testing in NSCLC patients

December 2023 Clinical Practice Jolien Blokken

Over the last decades, a greater understanding of the disease biology of non-small cell lung cancer (NSCLC) and the identification of recurrent oncogenic driver alterations has dramatically improved the therapeutic landscape. Indeed, we have moved away from a one-size-fits-all approach to a more personalized treatment strategy in which patients with a specific oncogenic driver mutations are treated with a suitable targeted therapy. However, to make this personalized treatment a reality, it needs to be accompanied by a fast and comprehensive molecular evaluation, allowing the accurate and timely detection of targetable oncogenic alterations. For this article, we asked Dr. Henry Paridaens, medical biologist at the Hôpital de la Citadelle in Liège to share how they currently approach the molecular testing of NSCLC patients.

In this interview Dr. Paridaens shares his insights on the following questions:

  • What is the current workflow for molecular testing in patients with NSCLC?
  • What is the rationale behind this strategy?
  • What are the major challenges with the strategy you are using?
  • How did the molecular testing for NSCLC patients evolve over the last years and which changes do you expect for the near future?

Read the complete interview here

This material is meant only for individuals allowed by law to prescribe or deliver medicines.

Copyright 2023 | PP-SE-BE-0149 NOV 2023

RP: Eli Lilly Benelux – Markiesstraat 1/4B Rue du Marquis, 1000 Brussel/Bruxelles